 |
BioWorld-Insight-2011-02-14
Big Pharma's Pipeline Purge Could Be Benefit to Biotechs
Drug Discovery Boundaries Blurring, Not Disappearing
Partnerships between academia and industry have been much in the news recently, with Pfizer Inc.'s deals with the University of California, San Francisco, and a deal between the Sanford-Burnham Research Institute and Ortho-McNeil-Janssen Pharmaceuticals Inc. as just two examples.